Denver, CO (ContentDesk) July 12, 2006 -- MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel therapeutic and prophylactic vaccines, today announced that animal model data showing the efficacy of its proprietary prophylactic vaccine against aspergillosis will be presented at the American Society for Microbiologys 46th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held in San Francisco September 27-30. These data represent a significant advancement in the companys development of vaccines to prevent human fungal infections. Importantly, this provides the critical proof of concept for a completely new antifungal vaccine strategy, said Dr. Claude P. Selitrennikoff, Ph.D., President and Chief Executive Officer of MycoLogics, Inc.About AspergillosisAspergillosis is the group of diseases caused by Aspergillus.

Patients that have received organ transplants or suffer lung conditions are particularly susceptible. In humans the three primary types of infections are allergic aspergillosis (affects asthma, cystic fibrosis and sinusitis patients), acute invasive aspergillosis, and disseminated invasive aspergillosis. Mortality rates in some patient populations are in excess of 60-70%. The consensus among the medical community is that a prophylactic vaccine which reduces this rate is sorely needed. About MycoLogics, Inc.MycoLogics, Inc., is an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, and the discovery and isolation of novel antifungal compounds for therapeutic use.

MycoLogics, Inc. is headquartered in Aurora, CO at the Fitzsimmons Colorado Bioscience Park. For more information please visit www.mycologics.com .CONTACT INFORMATION:Dr. Claude P. Selitrennikoff, Ph.D.President and CEOMycoLogics, Inc.Colorado Bioscience Park12635 East Montview Blvd., Aurora, CO 80010Tel: (303) 548-5017.